There has been no
actual clinical report on the changes in bone turnover markers and bone mineral
density (BMD) during ibandronate (IBN) treatment with or without vitamin D in
Japanese postmenopausal osteoporotic patients.
In this study, 48
treatment-naïve primary osteoporotic patients were divided into the IBN group
or IBN with alfacalcidol (ALF) group. Bone turnover markers, 1,25(OH)2D3,
and whole parathyroid hormone (PTH) were examined just prior to treatment
and at 1, 4, 8, 12, 16, and 20 weeks of therapy.
BMD was measured
at 0 and 16 weeks. Values of TRACP-5b were significantly and continuously lower
than baseline after 1 week of treatment in both groups.
No comments:
Post a Comment